Showing results (231-240 of 258) with videos related to
Sort By:
Pageof 26
Medical Oncology (Northwood, London, England)|June 2, 2018
Phase II study of panitumumab combined with capecitabine and oxaliplatin as first-line treatment in metastatic colorectal cancer patients: clinical results including extended tumor genotypingGeorge Papaxoinis, Vassiliki Kotoula, Eleni Giannoulatou, et al.Plos One|October 4, 2016
Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group StudyFlora Stavridi, Konstantine T Kalogeras, Kyriaki Pliarchopoulou, et al.Plos One|December 7, 2018
Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) studyAngelos Koutras, Georgios Lazaridis, Georgia-Angeliki Koliou, et al.Oncotarget|November 28, 2018
Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancerElena Fountzilas, Vassiliki Kotoula, Ioannis Tikas, et al.International Journal of Cancer|September 1, 2017
Prevalent somatic BRCA1 mutations shape clinically relevant genomic patterns of nasopharyngeal carcinoma in Southeast EuropeGeorge Fountzilas, Amanda Psyrri, Eleni Giannoulatou, et al.Oncotarget|April 30, 2016
TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant settingGeorge Fountzilas, Eleni Giannoulatou, Zoi Alexopoulou, et al.Journal of Cancer Research and Clinical Oncology|March 6, 2014
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximabEvangelia Razis, George Pentheroudakis, George Rigakos, et al.Anticancer Research|April 7, 2019
Association of Notch and Hedgehog Pathway Activation With Prognosis in Early-stage Colorectal CancerGrigorios Rallis, Triantafyllia Koletsa, Zenia Saridaki, et al.BMC Cancer|July 17, 2014
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trialGeorge Fountzilas, Urania Dafni, Christos Papadimitriou, et al.British Journal of Cancer|May 24, 2022
Dose-dense sequential adjuvant chemotherapy in the trastuzumab era: final long-term results of the Hellenic Cooperative Oncology Group Phase III HE10/05 TrialFlora Zagouri, Georgia-Angeliki Koliou, Foteinos Dimitrakopoulos, et al.Pageof 26